These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 27371575)

  • 1. CDK4/6 Inhibitors: Promising Opportunities beyond Breast Cancer.
    Lim JS; Turner NC; Yap TA
    Cancer Discov; 2016 Jul; 6(7):697-9. PubMed ID: 27371575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.
    Patnaik A; Rosen LS; Tolaney SM; Tolcher AW; Goldman JW; Gandhi L; Papadopoulos KP; Beeram M; Rasco DW; Hilton JF; Nasir A; Beckmann RP; Schade AE; Fulford AD; Nguyen TS; Martinez R; Kulanthaivel P; Li LQ; Frenzel M; Cronier DM; Chan EM; Flaherty KT; Wen PY; Shapiro GI
    Cancer Discov; 2016 Jul; 6(7):740-53. PubMed ID: 27217383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Kwapisz D
    Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
    Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
    Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer.
    Robert M; Frenel JS; Bourbouloux E; Rigaud DB; Patsouris A; Augereau P; Gourmelon C; Campone M
    Drugs; 2018 Sep; 78(13):1353-1362. PubMed ID: 30143968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical development of CDK4/6 inhibitor for breast cancer.
    Iwata H
    Breast Cancer; 2018 Jul; 25(4):402-406. PubMed ID: 29392622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of cyclin-dependent kinases 4 and 6 in breast cancer.
    Mayer EL
    Clin Adv Hematol Oncol; 2015 Apr; 13(4):215-7. PubMed ID: 26352578
    [No Abstract]   [Full Text] [Related]  

  • 8. Abemaciclib (Verzenio)--a third CDK 4/6 inhibitor for breast cancer.
    Med Lett Drugs Ther; 2017 Nov; 59(1533):185-186. PubMed ID: 29125595
    [No Abstract]   [Full Text] [Related]  

  • 9. CDK4/6 blockade in breast cancer: current experience and future perspectives.
    Zardavas D; Pondé N; Tryfonidis K
    Expert Opin Investig Drugs; 2017 Dec; 26(12):1357-1372. PubMed ID: 29027483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell cycle inhibitors make progress.
    Brower V
    J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 25006194
    [No Abstract]   [Full Text] [Related]  

  • 11. Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.
    Kwapisz D
    Breast Cancer; 2018 Sep; 25(5):506-516. PubMed ID: 29700711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
    Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC
    Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
    Parylo S; Vennepureddy A; Dhar V; Patibandla P; Sokoloff A
    J Oncol Pharm Pract; 2019 Jan; 25(1):110-129. PubMed ID: 29726787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update.
    O'Sullivan CC
    Expert Opin Pharmacother; 2016 Aug; 17(12):1657-67. PubMed ID: 27322766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer.
    Martin M; Garcia-Saenz JA; Manso L; Llombart A; Cassinello A; Atienza M; Ringeisen F; Ciruelos E
    Future Oncol; 2020 Nov; 16(33):2763-2778. PubMed ID: 32781837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclin-dependent kinase pathways as targets for women's cancer treatment.
    Konecny GE
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):42-8. PubMed ID: 26642065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer.
    Palumbo A; Lau G; Saraceni M
    Ann Pharmacother; 2019 Feb; 53(2):178-185. PubMed ID: 30099886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic drug evaluation of abemaciclib for advanced breast cancer.
    Robert M; Frenel JS; Bourbouloux E; Berton Rigaud D; Patsouris A; Augereau P; Gourmelon C; Campone M
    Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):85-91. PubMed ID: 30577708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cell cycle inhibitors in endocrine receptor positive breast cancer].
    Sablin MP; Ricci F; Loirat D; Jobard A; Basse C; Romano E; Le Tourneau C; Dieras V
    Bull Cancer; 2017 Feb; 104(2):114-122. PubMed ID: 28126188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDK4-6 inhibitors in breast cancer: current status and future development.
    Choo JR; Lee SC
    Expert Opin Drug Metab Toxicol; 2018 Nov; 14(11):1123-1138. PubMed ID: 30360668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.